Wednesday, June 1, 2011
Vivus Inc., of Mountain View, Calif., presented several posters at the European Congress on Obesity in Istanbul, Turkey, including data that showed Qnexa (phentermine/topiramate) reduced progression to Type II diabetes and improved glycemic status in patients defined as prediabetics at baseline. In the prediabetic population from the CONQUER study, significantly more Qnexa-treated patients achieved normal blood sugar levels (p = 0.0016) and significantly more patients in the placebo arm progressed to Type II diabetes (p = 0.0253). Qnexa was rejected by the FDA last year, but Vivus plans to resubmit a new drug application in the fourth quarter of this year.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.